Results 101 to 110 of about 105,518 (257)

Characterizing the Epithelial Transcriptome of Type‐2 High Chronic Rhinosinusitis

International Forum of Allergy &Rhinology, EarlyView.
Brian Cameron, Jeffanie Gayoso, Christina Dorismond, Ping Li, Mason Krysinski, Rakesh Chandra, Justin Turner, Naweed Chowdhury   +7 more
wiley   +1 more source

Trans‐Tendon Suture‐Bridge Knotless Proximal Pulley Repair With Bioinductive Patch Augmentation for High‐Grade Partial Hip Abductor Tendon Tears

Arthroscopy Techniques, EarlyView.
Abstract This technical note describes a knotless trans‐tendon proximal‐pulley repair with distal suture‐bridge fixation and bioinductive collagen patch augmentation for high‐grade partial gluteus medius and minimus tears. The technique preserves intact tendon fibers, restores broad footprint compression, and supports biologic healing through a ...
Maria Agustina Olarán, Napatpong Thamrongskulsiri, Felipe Casanova, Tomás F. Vega, Jorge Sánchez‐Mateos, Tanner Nishioka, Jorge Chahla   +6 more
wiley   +1 more source

Gluteal Undersurface Concealed Crescent Injury Endoscopic Deep Surface Repair

Arthroscopy Techniques, EarlyView.
Abstract Partial‐thickness articular‐sided gluteus medius and minimus tears—referred to as gluteal undersurface concealed crescent injury lesions—can cause debilitating pain. Persistent symptoms despite nonoperative care indicate operative management. Conventional endoscopic repair techniques for partial‐thickness gluteal tears have commonly involved a
Bryant P. Elrick, Judas Z. Kelley, Eric Welder, Cody Ramirez, Benjamin L. Judkins, James W. Genuario   +5 more
wiley   +1 more source

Zuranolone: A case study in (regulatory) rush to judgement?

British Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove, Milutin Kostic, Barbara Mintzes, Gianna D'Ambrozio, Allen Shaughnessy   +4 more
wiley   +1 more source

Safety concerns reported by coroners following fentanyl patch fatalities in England, Wales and Northern Ireland between 1997 and 2024

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim To identify safety concerns reported by coroners following fentanyl patch‐related deaths in England, Wales and Northern Ireland, and determine differences in coronial reporting. Methods A systematic case series linking the National Programme on Substance Use Mortality (NPSUM) and the Preventable Deaths Tracker (PDT) (https ...
Eman Mshari, Caroline S. Copeland, Georgia C. Richards   +2 more
wiley   +1 more source

Pregnancy‐related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosis

British Journal of Clinical Pharmacology, EarlyView.
Aim The number of pregnancies among women with cystic fibrosis (wwCF) has steadily increased over the past decade. However, the pharmacokinetics (PK) of elexacaftor–tezacaftor–ivacaftor (ETI) during gestation remains uncharacterized, despite its widespread use in this population.
Paulette Magnas, Naim Bouazza, Frantz Foissac, Saïk Urien, Léo Froelicher‐Bournaud, Gabrielle Lui, Victoria Guillemart, Nicolas Carlier, Jennifer Da Silva, Johanna Fesenbeckh, Reem Kanaan, Isabelle Honoré, Clémence Martin, Jean‐Marc Treluyer, Vassilis Tsatsaris, Pierre‐Régis Burgel, Sihem Benaboud   +16 more
wiley   +1 more source

Geriatrician and General Internist Clinical Payments in Canada 2022-2023: Fee for Service and Alternative Payment Plan. [PDF]

Can Geriatr J
Martel AB, Mah JC, Shu KJ, Bhangu JS, Borrie MJ.   +4 more
europepmc   +1 more source

Cardiovascular and neuropsychiatric outcomes with PCSK9 inhibitors in atherosclerotic cardiovascular disease: A retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
Study design and main findings. After 1:1 propensity score matching, 60 885 PCSK9 inhibitor users and 60 885 statin‐only users with ASCVD were compared. Kaplan–Meier curves show 12‐month cumulative event‐free survival for MACE, psychiatric disease, and neurodegenerative disease.
Tianshu Gu, Yang Chen, Nan Zhang, Uazman Alam, Riccardo Proietti, Tong Liu, Kang‐Yin Chen, Gregory Y. H. Lip   +7 more
wiley   +1 more source

Medicare costs and home time loss among fee-for-service beneficiaries by frailty and dementia status. [PDF]

J Frailty Aging
Sison SDM, Zhong L, Oh G, Shi SM, Park CM, Olivieri-Mui B, McCarthy EP, Kim DH.   +7 more
europepmc   +1 more source

Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real‐world data

British Journal of Clinical Pharmacology, EarlyView.
Aims The glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) semaglutide and liraglutide are approved for chronic weight management. Both drugs also have favourable effects on the risk of developing diabetes and cardiovascular disease (CVD) compared with placebo, but their comparative effectiveness for these outcomes is unclear.
Ethan J. Cannon, Wendy Wang, Faye L. Norby, Rob F. Walker, Shalini Kulasingam, Lisa S. Chow, Joel F. Farley, Pamela L. Lutsey   +7 more
wiley   +1 more source